Embecta (FRA:JX7) Asset Impairment Charge : €0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Embecta Asset Impairment Charge?

Embecta's Asset Impairment Charge for the three months ended in Mar. 2024 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was €0 Mil.

Embecta Asset Impairment Charge Historical Data

The historical data trend for Embecta's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Asset Impairment Charge Chart

Embecta Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

Asset Impairment Charge

11.73

59.49

2.34

Embecta Quarterly Data
	Sep19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial											-	-	-	-	-

Embecta Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Embecta Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Embecta's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Embecta (FRA:JX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

EMBC:USA JX7:Germany

Address

300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054

Website

https://www.embecta.com

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines